The Efficacy And Safety Analysis Of Anlotinib In The Treatment For Advanced Non-small Cell Lung Cancer

Objective:This study is designed to research the efficacy,safety and survival time of anlotinib in the treatment for patients with advanced non-small cell lung cancer.Menthod:Retrospective analysis the data of treatment with anlotinib in 64 patients with advanced non-small cell lung cancer who had progressed more than 2 standard chemotherapies via the First Affiliated Hospital of Wannan Medical College from January 01,2019 to June 01,2020.Results:1.A total of 64 patients were enrolled.According to the response evaluation criteria in solid tumors1.1,there were 0 cases of complete remission,6 cases of partial remission(9.4%),49 cases of stable disease(76.5%)and 9 cases of disease progression(14.1%).The overall objective response rate was 9.4%(6/64),and the overall disease control rate was 85.9 %(55/64).2.After 2 cycles treatment of anlotinib,serum VEGF and tumour markers CEA,CA125 and CYFRA21-1 were rechecked.The results showed that the expression of all indicators were significantly decreased overall(P<0.05),while the 9 patients who progressed,these indicators increased to varying degrees(P<0.05).3.Anlotinib had a good safety profile with 25 patients experiencing varying degrees of toxicities,mainly grade 1-2,with hypertension being the most common(32.8%),followed by hypertriglyceridemia(20.3%),hand-foot skin reaction(18.8%),hypothyroidism(15.6%)and proteinuria(14.1%),all of which were within the patient tolerance.3 patients developed side effects of high blood pressure ≥grade 3 after taking The drug,while no discontinuation occurred through dose adjustment and antihypertensive treatment.4.The median progression-free survival was 6.93 months(95%CI: 5.67-8.19).The risk factors for patient survival were smoking history and pathological type(P<0.05),independent of other baseline characteristics such as age,gender,TNM stage and ECOG score(P>0.05).Conclusion: 1.Anlotinib targeted therapy is highly effective in treating patients with advanced NSCLC,with mild and easily tolerated side effects,an ORR of 9.4% and a DCR of 85.9%,and a significant survival benefit for patients.2.After treatment with anlotinib,the patient’s m PFS was 6.93±0.64 months(95%CI:5.67-8.19).Smoking history and pathological type were the main factors affecting survival risk factors.3.There was a significant improvement in the overall expression of serum VEGF and tumor markers in patients after treatment with anlotinib(P<0.05).